Your browser doesn't support javascript.
loading
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Lucas, Claire M; Harris, Robert J; Giannoudis, Athina; Davies, Andrea; Knight, Katy; Watmough, Sarah J; Wang, Lihui; Clark, Richard E.
Affiliation
  • Lucas CM; Department of Haematology, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK.
Haematologica ; 94(10): 1362-7, 2009 Oct.
Article in En | MEDLINE | ID: mdl-19713230
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Haematologica Year: 2009 Document type: Article Affiliation country: United kingdom Country of publication: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Haematologica Year: 2009 Document type: Article Affiliation country: United kingdom Country of publication: Italy